182 related articles for article (PubMed ID: 8899255)
1. Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro-progestins.
Olivieri O; Friso S; Manzato F; Grazioli S; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C; Corrocher R
Contraception; 1996 Sep; 54(3):149-52. PubMed ID: 8899255
[TBL] [Abstract][Full Text] [Related]
2. Resistance to activated protein C in healthy women taking oral contraceptives.
Olivieri O; Friso S; Manzato F; Guella A; Bernardi F; Lunghi B; Girelli D; Azzini M; Brocco G; Russo C
Br J Haematol; 1995 Oct; 91(2):465-70. PubMed ID: 8547095
[TBL] [Abstract][Full Text] [Related]
3. Resistance to activated protein C, highly prevalent amongst users of oral contraceptives with venous thromboembolism.
Bennet L; Odeberg H
J Intern Med; 1998 Jul; 244(1):27-32. PubMed ID: 9698021
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral contraceptives on hemostasis and thrombosis.
Rosing J; Tans G
Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S375-82. PubMed ID: 10368524
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
[TBL] [Abstract][Full Text] [Related]
6. Contraceptive choices in women with coagulation disorders.
Comp PC; Zacur HA
Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):1990-3. PubMed ID: 8512043
[TBL] [Abstract][Full Text] [Related]
7. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
[TBL] [Abstract][Full Text] [Related]
8. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden.
Rintelen C; Mannhalter C; Ireland H; Lane DA; Knöbl P; Lechner K; Pabinger I
Br J Haematol; 1996 May; 93(2):487-90. PubMed ID: 8639453
[TBL] [Abstract][Full Text] [Related]
9. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives.
Rosing J; Tans G; Nicolaes GA; Thomassen MC; van Oerle R; van der Ploeg PM; Heijnen P; Hamulyak K; Hemker HC
Br J Haematol; 1997 Apr; 97(1):233-8. PubMed ID: 9136971
[TBL] [Abstract][Full Text] [Related]
11. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients.
Girolami A; Simioni P; Girolami B; Zanardi S
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):673-8. PubMed ID: 1782339
[TBL] [Abstract][Full Text] [Related]
12. Coagulation and anticoagulation effects of contraceptive steroids.
Samsioe G
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1523-7. PubMed ID: 8178901
[TBL] [Abstract][Full Text] [Related]
13. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
15. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
16. Factor V Leiden and pulmonary embolism in a young woman taking an oral contraceptive.
DiSiena MR; Intres R; Carter DJ
Am J Forensic Med Pathol; 1998 Dec; 19(4):362-7. PubMed ID: 9885932
[TBL] [Abstract][Full Text] [Related]
17. Factor V Leiden: should we screen oral contraceptive users and pregnant women?
Vandenbroucke JP; van der Meer FJ; Helmerhorst FM; Rosendaal FR
BMJ; 1996 Nov; 313(7065):1127-30. PubMed ID: 8916702
[TBL] [Abstract][Full Text] [Related]
18. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
Norris LA; Bonnar J
Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
[TBL] [Abstract][Full Text] [Related]
19. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
20. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis.
Andersen BS; Olsen J
Thromb Res; 1998 May; 90(4):191-4. PubMed ID: 9692618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]